Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases, and exploring their potential to provide deep, durable, and potentially curative responses. Our proprietary technology utilizes chimeric autoantibody receptor, or CAAR, T cells that are designed to selectively bind and eliminate the pathogenic B cells that express disease-causing autoantibodies while sparing normal B cells, leaving the healthy immune system intact. Our technology, in combination with our proprietary Cabaletta Approach for selective B cell Ablation (CABA™) platform, has applicability across more than two dozen B cell-mediated autoimmune diseases. Using our CABA™ platform, we have discovered and developed five disclosed product candidates, including our lead clinical-stage therapy in development to treat patients with mucosal pemphigus vulgaris. We hold multiple agreements with the University of Pennsylvania and other academic institutions to develop CAAR T cell therapies. Our goal is to leverage our team’s expertise in autoimmunity and engineered T cell therapy and our network of collaborators to rapidly discover and develop our portfolio of CAAR T product candidates.
Pharmaceutical Preparation Manufacturing (325412)
Pharmaceutical Preparations (2834)